^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    VEGF-A inhibitor

    Related drugs:
    19h
    Modified Short-Course Radiotherapy Combined With Immunochemotherapy and Targeted Therapy as First-Line Treatment for MSS Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, Sir Run Run Shaw Hospital
    New P2 trial
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr)
    23h
    A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=375, Recruiting, BioNTech SE | Trial completion date: Mar 2028 --> Aug 2028
    Trial completion date • First-in-human
    |
    pumitamig (BNT327)
    1d
    Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases (clinicaltrials.gov)
    P3, N=220, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab)
    2d
    POCHI: Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate (clinicaltrials.gov)
    P2, N=55, Recruiting, Federation Francophone de Cancerologie Digestive | Not yet recruiting --> Recruiting
    Enrollment open • Tumor mutational burden
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • capecitabine • oxaliplatin
    4d
    FMT Combined With Standard First-Line Therapy in Initially Unresectable Colorectal Cancer (clinicaltrials.gov)
    P2/3, N=220, Not yet recruiting, Shanghai 10th People's Hospital
    New P2/3 trial
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • irinotecan
    4d
    Toco-CoR: Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=83, Active, not recruiting, Vejle Hospital | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Avastin (bevacizumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium
    5d
    Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, University of Wisconsin, Madison | Active, not recruiting --> Recruiting | N=25 --> 50 | Trial completion date: Jul 2026 --> Jul 2028 | Trial primary completion date: Jul 2026 --> Jul 2028
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 positive • RAS wild-type • RAS wild-type + HER-2 positive • HER-2 positive + RAS wild-type
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • Onivyde (nanoliposomal irinotecan)
    5d
    PAVILION: A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (clinicaltrials.gov)
    P3, N=174, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    Lucentis (ranibizumab)
    5d
    ROSETTA GI 204: A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) (clinicaltrials.gov)
    P2/3, N=690, Recruiting, Bristol-Myers Squibb | N=184 --> 690
    Enrollment change • Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    Opdivo (nivolumab) • 5-fluorouracil • pumitamig (BNT327)
    5d
    High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis (clinicaltrials.gov)
    P2, N=46, Completed, Sun Yat-sen University | Recruiting --> Completed | N=30 --> 46
    Trial completion • Enrollment change
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Avastin (bevacizumab) • pemetrexed • Ivesa (firmonertinib)
    6d
    A review of the current evidence for maintenance therapy in gastric cancer. (PubMed, Front Pharmacol)
    Among them, capecitabine, S-1, bevacizumab, and avelumab were most frequently evaluated. MT, whether applied as a continuous or switching strategy, may sustain clinical benefits without compromising QoL due to severe AEs. Future studies should investigate the long-term clinical benefits of MT and its impact on resource utilization and health-related QoL.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
    |
    Avastin (bevacizumab) • Bavencio (avelumab) • capecitabine
    6d
    A Phase 1 Study of the Safety and Tolerability of CTX-10726 (clinicaltrials.gov)
    P1, N=70, Recruiting, Compass Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    PD-L1 (Programmed death ligand 1)
    |
    MSI-H/dMMR